Avantor Unveils New Sugars at CPhI
The new sugars are touted to increase the efficacy of active pharmaceutical ingredients and improve cell culture yield.
Avantor Performance Materials introduced new J.T. Baker High Purity Low Endotoxin (HPLE) sugars at Avantor’s Advance Biopharmaceuticals exhibit during the 2015 CPhI meeting on Oct. 13, 2015. According to the company, the sugars improve cell-culture yield, boost the efficacy of pharmaceutical ingredients, and enhance patient safety.
Specifically, the sugars decrease the probability that degradation will occur during fill/finish processes and help preserve a protein’s integrity during and after lyophilization, says Avantor’s Chief Commercial Officer Roland Heinrich, PhD. “We’ve expanded our manufacturing capabilities to purify bioexcipients using proprietary purification technology,” said Heinrich. As a result, the new sugars are able to “achieve endotoxin levels that are consistently below regulatory requirements and contain industry-leading low impurity levels,” he added.
Source: Avantor
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
